STOCK TITAN

PPBT 6-K: press release on IM1240 tri-specific antibody milestone

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Purple Biotech Ltd. furnished a Form 6-K noting it issued a press release titled “Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform.” The press release is included as Exhibit 99.1 and is dated October 29, 2025.

The filing is administrative and points readers to the attached press release for details on the IM1240 manufacturing milestone from the CAPTN-3 platform.

Positive

  • None.

Negative

  • None.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

 

For the month of October 2025

 

Commission File Number: 001-37643

 

PURPLE BIOTECH LTD.

(Translation of registrant’s name into English)

 

4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F Form 40-F

 

 

 

 

 

Purple Biotech

 

On October 29 , 2025, Purple Biotech Ltd. (the “Company” or the “Registrant”) issued a press release “Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform, which is attached hereto as Exhibit 99.1.

 

Exhibit    
99.1   Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

October 29, 2025 PURPLE BIOTECH LTD.
   
  By:  /s/ Gil Efron
    Gil Efron
    Chief Executive Officer

 

2

FAQ

What did Purple Biotech (PPBT) file?

The company furnished a Form 6-K reporting it issued a press release on an IM1240 manufacturing milestone.

What is the subject of the press release in PPBT’s 6-K?

A manufacturing milestone for IM1240, a tri-specific antibody from the CAPTN-3 platform.

When was the Purple Biotech press release issued?

The press release is dated October 29, 2025.

Where can I find the press release within the 6-K?

It is attached as Exhibit 99.1.

Does the 6-K include financial results for PPBT?

No. It furnishes a press release regarding a manufacturing milestone for IM1240.
Purple Biotech Ltd

NASDAQ:PPBT

PPBT Rankings

PPBT Latest News

PPBT Latest SEC Filings

PPBT Stock Data

5.63M
8.43M
7.13%
4.29%
3.13%
Biotechnology
Healthcare
Link
Israel
Rehovot